Robert Garry
Professor | Tulane University
New Orleans, LA, UNITED STATES
Dr. Garry has published over 100 papers in the area of retrovirology
Media
Publications:
Documents:
Photos:
Videos:
Audio/Podcasts:
Biography
In 1983 Dr. Garry was appointed Assistant Professor of Microbiology and Immunology at Tulane University School of Medicine in New Orleans, Louisiana. In 1985 he was Visiting Professor of Pathology at the University of Southern California working with Dr. Suraiya Rasheed. Dr. Garry spent 1991 as a Visiting Professor of Molecular Biology at the University of Hamburg working with Dr. Gebhard Koch. Since 1993 he has been Professor of Microbiology and Immunology at Tulane Medical School. Dr. Garry has published over 100 papers in the area of retrovirology. Research in the Garry Laboratory focuses on a number of aspects of retroviral pathogenesis. Investigations have found that HIV induces a number of defects in plasma membrane ion transport, which could account for the loss of CD4+ T-cells in AIDS patients. Another research interest is the molecular characterization of an isolate of HIV from a patient who died of AIDS in 1969. This is the earliest confirmed case of AIDS in the United States. In addition, the lab has discovered a retrovirus named human intracisternal A-type retroviral particle (HIAP), which appears to be involved in systemic autoimmune diseases and idiopathic CD4 T-lymphocytopenia. More recently, the lab obtained evidence for the existance of a human endogenous retrovirus named human mammary tumor virus (HMTV), which is a close homolog of a virus which causes breast cancer in mice.
Dr. Garry is currently managing a consortium of scientists who are developing countermeasures, including diagnostics, immunotherapeutics and vaccines, against Lassa virus, Ebola and Marburg viruses, and other high consequence pathogens. Our team has produced Lassa fever and Ebola point-of-care and confirmatory diagnostics based on recombinant proteins. A combination of human monoclonal antibodies has been shown to rescue 100% of monkeys even when treatment is initiated at an advanced stage of disease. Studies on a combination Lassa fever and Ebola vaccine for use in West Africa have been initiated. Productive collaborations have been exploited to deepen understanding of the natural history of viral hemorrhagic fevers while providing training for West African scientists and further developing research and clinical trial infrastructure in Sierra Leone and Nigeria.
Areas of Expertise (10)
COVID-19
Pathology
Lassa Fever
Molecular Mechanisms of Viral Pathogenesis
Ebola
Virology
Marburg Virus
Immunotherapy
Lassa Virus
Coronavirus
Education (2)
University of Texas at Austin: Ph.D., Microbiology 1978
Indiana State University: B.S., Life Sciences 1978
Links (3)
Media Appearances (3)
Many in West Africa May Be Immune to Ebola Virus
The New York Times
2014-09-05
“It’s fair to say that some people are immune,” said Robert F. Garry Jr., a Tulane University expert in hemorrhagic fevers who works in Sierra Leone. “But we don’t know if it’s 1 percent or 2 percent or 20 percent.”
Bloggers: Bill and Melinda Gates, George Soros funded Sierra Leone lab that started Ebola outbreak
Politifact
2014-08-11
"We were there working 10 years and then Ebola came here," said Dr. Robert Garry, a Tulane University professor and program manager of the consortium. "We’re not here to turn Lassa and Ebola into a kind of superweapon. It can do that on its own."
Growing Ebola Outbreak Threatens to Overwhelm Volunteers
NBC News
2014-06-08
“This is worse than expected. I am fearful that it could get much worse,” said Robert Garry, a virologist and specialist in viral hemorrhagic fevers at Tulane University. Garry flew to Kenema Government Hospital last month with as much personal protective equipment (PPE) as he could carry, but he says they are running out fast.
Articles (3)
Proteomics Computational Analyses Suggest that the Antennavirus Glycoprotein Complex Includes a Class I Viral Fusion Protein (α-Penetrene) with an Internal Zinc-Binding Domain and a Stable Signal
VirusesCourtney E. Garry, Robert F. Garry
2019 A metatranscriptomic study of RNA viruses in cold-blooded vertebrates identified two related viruses from frogfish (Antennarius striatus) that represent a new genus Antennavirus in the family Arenaviridae (Order: Bunyavirales). Computational analyses were used to identify features common to class I viral fusion proteins (VFPs) in antennavirus glycoproteins, including an N-terminal fusion peptide, two extended alpha-helices, an intrahelical loop, and a carboxyl terminal transmembrane domain.
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization
CellKathryn M. Hastie, Robert William Cross, Stephanie S. Harkins, Michelle A. Zandonatti, Anatoliy Koval, Megan L Heinrich, Megan M. Rowland, James E. Robinson, Thomas W. Geisbert, Robert F. Garry, Luis M. Branco, Erica Ollmann Saphire
2019 Lassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa. Protective antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group antibodies often show potent neutralizing activity in humans. However, which features confer potent and broadly neutralizing antibody responses is unclear. Here, we compared three crystal structures of LASV GPC complexed with GPC-B antibodies of varying neutralization potency.
Antibody therapy for Lassa fever
Current Opinion in VirologyRobert William Cross, Kathryn M Hastie, Chad E Mire, James E Robinson, Thomas W Geisbert, Luis M Branco, Erica Ollmann Saphire, Robert F Garry
2019 Serum from convalescent Lassa fever patients was previously shown to be ineffective as a source of protective antibodies in some early studies. Subsequently, monoclonal antibodies (MAbs) to the Lassa virus (LASV) glycoprotein produced by memory B cells of West African patients who survived Lassa fever were identified. Development of MAbs as potential Lassa immunotherapeutics was facilitated by structural studies and mutational analyses that identified protective epitopes on the prefusion form of the LASV glycoprotein.
